In-silico Characterization of Target Protein in Dengue Infection

Authors

  • Vinod P Sinoorkar  Department of PG Studies and Research in Bioinformatics, , Solapur, Maharashtra, India
  • Umme Aiman Md. S. Kumthe  Walchand Center for Biotechnology, Solapur, Maharashtra, India

DOI:

https://doi.org//10.32628/IJSRST229627

Keywords:

Dengue Infection, Viral fever, DC-SIGN, Host protein, DENV.

Abstract

Infection of humans with the virus is primarily mediated by the Aedes mosquito. The virus grows in the mosquito gut and migrates to aq 1 the salivary glands.. Dengue virus (DENV), which includes four serotypes (DENV1–4), is transmitted to humans by Aedes mosquitos and is the etiological agent of dengue fever and dengue hemorrhagic fever. DENV causes an estimated 50–100 million cases of dengue fever, 500,000 cases of severe dengue (dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS)), and more than 20,000 deaths each year in tropical and subtropical regions, representing a considerable public health threat in over 100 countries worldwide. However, there are still no specific antiviral drugs or licensed vaccines against DENV infection. Dengue virus primarily propagates in skin dendritic cells, and subsequently virus proliferation is thought to occur in target cells such as those of the monocyte/macrophage lineage. Second, carbohydrate binding proteins, termed lectins, expressed on dendritic cells (DCs) and macrophages under the human skin are involved in initial contact of DENV introduced by mosquito bite. Among these lectins, dendritic cell-specific intercellular adhesion molecule-3-grabbing non integrin (DCSIGN) has been best characterized in virus-DC interaction.

References

  1. Monath, T. P. and Heinz, F.X. (1996) Flaviviruses. In fields of Virology. (Eds) 3rd edition pp 961-1034. Lippincott-Raven, Philadelphia. Indian Journal of Clinical Biochemistry, 2005.
  2. Javanmardia J, Stushnoff C, Lockeb E, Vivancob J M. Antioxidant activity and total phenolic content of Iranian Ocimum accessions: Food Chem 2003.
  3. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, et al. Strategies for development of dengue virus inhibitors. Antiviral Res. 2010.
  4. Lucas Cunha Dias de Rezende, Victor Hugo Aquino and Flavio da Silva Emery. DENGUE FEVER Recent Advances in the Discovery of Small Organic Molecules for the Prevention and Treatment of Dengue Fever.1999.
  5. Kielian, M.C. and Helenius. (1986) A "Role of cholesterol in fusion of Semliki Forest virus with membranes" J. Virol. pp. R565-R569. Indian Journal of Clinical Biochemistry, 2005.

Downloads

Published

2022-12-30

Issue

Section

Research Articles

How to Cite

[1]
Vinod P Sinoorkar, Umme Aiman Md. S. Kumthe, " In-silico Characterization of Target Protein in Dengue Infection, International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 9, Issue 6, pp.215-218, November-December-2022. Available at doi : https://doi.org/10.32628/IJSRST229627